Addex And Merck & Co., Inc. Collaborate To Develop Drugs For Parkinson’s Disease

Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced that it has entered an exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd) with the goal of developing a new class of orally available drugs, initially as candidates for the treatment of Parkinson’s disease and potentially other undisclosed indications. [click link for full article]

More: continued here

Filed under: Parkinson's Disease on December 6th, 2007